Needham analyst Ami Fadia downgraded Sage Therapeutics to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SAGE:
- Sage Therapeutics downgraded to Hold at Canaccord after Zurzuvae CRL
- Sage Therapeutics downgraded to Neutral from Buy at Goldman Sachs
- Sage Therapeutics price target lowered to $19 from $45 at Mizuho
- Sage Therapeutics price target lowered to $27 from $50 at H.C. Wainwright
- Sage Therapeutics downgraded to Hold from Buy at Canaccord